AVLN

About Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

CEO: Lyn Baranowski
IPO Date: Apr 30, 2026

Market Data

Volume: 272.3K

Valuation

Market Cap: $1.2B

Financials

Financial statement snapshot is not available yet.